Cancer immunotherapy biotech Tessa Therapeutics names industry veteran to board

IN a sign that it could be progressing towards certain milestones, Singapore-based immunotherapy biotech company Tessa Therapeutics continued to shore up its board of directors with another independent member on Friday.

In April 2018, the company appointed former Novo Nordisk chairman Goran Ando to the board. This was followed in December 2018 with the appointment of Dr George Sledge, chief of medical oncology at Stanford University Medical Centre. Tessa counts Singapore government-owned investment firm Temasek Holdings as an investor. In 2017, Temasek led a US$80 million funding round into Tessa, alongside Heliconia Capital and EDBi. An additional US$50 million was raised in 2018, lifting the round's total to US$130 million, according to a company spokesperson.

المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين

Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.

How to better regulate the pet boarding industry
مصدر: TODAYonline - 🏆 1. / 99 اقرأ أكثر »

Beauty industry chalks up most complaints in 2018; watchdog flags ugly practices
مصدر: TODAYonline - 🏆 1. / 99 اقرأ أكثر »

Industry body unveils fintech accelerator and mentorship programme for asset managersTHE Investment Management Association of Singapore (IMAS) has launched a fintech accelerator and mentorship programme for asset managers. Read more at The Business Times.
مصدر: BusinessTimes - 🏆 15. / 51 اقرأ أكثر »

US lawmakers, industry fret over Trump's China trade deal eagernessWASHINGTON: President Donald Trump's decision to delay a steep tariff hike on Chinese goods as he touted progress in weekend trade talks was ...
مصدر: ChannelNewsAsia - 🏆 6. / 66 اقرأ أكثر »